European Pharmaceutical Review

JANUARY 9, 2024

Pfizer’s oral poly ADP-ribose polymerase (PARP) inhibitor TALZENNA ® (talazoparib), in combination with XTANDI ® (enzalutamide) has been approved for prostate cancer by the European Commission (EC). This results in less cancer cell growth and death, according to Pfizer in a statement.

Chemotherapy 90

Chemotherapy FDA 90

The Checkup by Singlecare

MAY 30, 2023

Most people have heard of the prostate, but only a few can tell you what it actually does. This small part of the male reproductive system plays a not-so-small role in male fertility by helping to produce semen, and the prostate’s proximity to the bladder means it can also impact urination. How does diet affect prostate health?

Compounding 98

Compounding 98

Pharmaceutical Technology

APRIL 17, 2024

Everolimus is under clinical development by Novartis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

52

52

pharmaphorum

NOVEMBER 29, 2021

A web-based digital tool called Helix could help clinicians identify patients with prostate cancer who would benefit from genetic testing and counselling, according to researchers in the US. In addition, just 43% correctly identified that BRCA2 mutations – treated with PARP inhibitors – are associated with aggressive prostate cancers.

98

98

European Pharmaceutical Review

MARCH 21, 2023

AstraZeneca and MSD’s treatment is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in first-line mCRPC.

Chemotherapy 95

Chemotherapy Hospitals 95

European Pharmaceutical Review

DECEMBER 5, 2022

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death.

Chemotherapy 101

Chemotherapy Compounding Labelling FDA 101

pharmaphorum

NOVEMBER 27, 2022

There are over 52,000 cases of prostate cancer each year in the UK alone, with over 15,000 new cases of metastatic prostate cancer confirmed annually. There are over 52,000 cases of prostate cancer each year in the UK alone, with over 15,000 new cases of metastatic prostate cancer confirmed annually.

Hospitals 98

Hospitals FDA 98

Pharmaceutical Technology

FEBRUARY 7, 2024

Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.

52

52

European Pharmaceutical Review

AUGUST 17, 2022

The MHRA has also issued a licence in Great Britain for Locametz ® (gozetotide) which, after radiolabelling with gallium-68, is a radioactive diagnostic agent indicated for the identification of PSMA-positive lesions by positron emission tomography (PET) in adult patients with prostate cancer. percent), dry mouth (38.8

Chemotherapy 117

Chemotherapy Compounding Labelling 117

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. The post NICE says no to Lynparza in prostate cancer, creating UK access divide appeared first on.

Chemotherapy 110

Chemotherapy 110

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer.

98

98

Pharmaceutical Technology

JUNE 1, 2023

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD ’s Lynparza (olaparib), with standard therapies for treating BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is the second-most common cancer reported in men.

FDA 97

FDA Chemotherapy 97

European Pharmaceutical Review

DECEMBER 21, 2022

Positive Phase III trial results for metastatic castration-resistant prostate cancer. The safety and tolerability of Lynparza in combination with abiraterone in PROpel was in line with that observed in prior clinical trials and the known profiles of the individual medicines.

Chemotherapy 99

Chemotherapy Hospitals 99

pharmaphorum

SEPTEMBER 22, 2021

Software that can help pathologists detect prostate cancer from slides of biopsies more effectively has been approved by the FDA. The software – called Paige Prostate – is the first artificial intelligence-based to be approved by the FDA for this purpose, according to the US regulator.

FDA 107

FDA 107

Pharmacy Times

JUNE 21, 2023

Clinical trial results showed that the combination significantly improved radiographic progression-free survival compared with enzalutamide monotherapy for homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

FDA 65

FDA 65

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Research Laboratories 105

Research Laboratories Vaccines 105

Hospital Pharmacy Europe

JANUARY 24, 2024

The poly ADP-ribose polymerase (PARP) inhibitor talazoparib (brand name Talzenna) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat a type of locally advanced or metastatic breast cancer. The trial did not show any difference in how long people live. So talazoparib is recommended.’

Chemotherapy 101

Chemotherapy Hospitals 101

Pharmaceutical Technology

FEBRUARY 19, 2024

AC-0176 is under clinical development by Accutar Biotechnology and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

FEBRUARY 7, 2024

CONV 01-alpha is under clinical development by Convergent Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

AUGUST 8, 2022

The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients. in trial subjects versus those who received ADT plus docetaxel.

FDA 98

FDA Chemotherapy 98

European Pharmaceutical Review

APRIL 4, 2024

Benefit of the advanced Ga-68 radiolabelling technology According to RLS, Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a major role in the diagnosis and treatment planning for patients with neuroendocrine tumours and prostate cancer.

86

86

pharmaphorum

SEPTEMBER 28, 2020

Shares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of efficacy in advanced prostate cancer in its first clinical trial. The trial involved patients with locally advanced or metastatic prostate cancer, so received VAL201 in rising doses by subcutaneous injection.

Hospitals 124

Hospitals 124

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The post Bayer triples sales forecast for prostate cancer drug Nubeqa appeared first on.

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

AUGUST 9, 2022

Magnetic resonance imaging (MRI) technology specialist Bot Image has won FDA approval for its artificial intelligence-powered software ProstatID, used for the detection and diagnosis of prostate cancer. The post FDA okays ProstatID software for detecting prostate cancer in MRI appeared first on.

FDA 82

FDA 82

pharmaphorum

JANUARY 26, 2023

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co’s checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. It remains ongoing with updated results due in the coming months.

Chemotherapy 58

Chemotherapy Immunization FDA 58

Pharmafile

OCTOBER 4, 2023

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of clinical and preclinical-stage radioligand therapies for the treatment of cancer.

69

69

European Pharmaceutical Review

AUGUST 14, 2023

The US Food and Drug Administration (FDA) has approved Janssen’s Akeega (niraparib and abiraterone acetate), for the treatment of adult patients BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). acquired by GlaxoSmithKline in 2019) for exclusive rights to niraparib in prostate cancer treatment.

FDA 52

FDA 52

European Pharmaceutical Review

MARCH 6, 2024

Keren Haruvi, President Sandoz North America highlighted that denosumab is a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events. Wyost Similarly, Wyost 120 mg/1.7 mL (70 mg/mL) injection is a human monoclonal antibody designed to bind to the RANKL protein.

FDA 95

FDA Dosage Labelling 95

Pharmaceutical Technology

FEBRUARY 27, 2023

Finnish pharmaceutical firm Orion has received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide plus androgen deprivation therapy (ADT) along with docetaxel to treat metastatic prostate cancer. It also demonstrated consistent benefits across clinically relevant secondary endpoints of the trial.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

FEBRUARY 7, 2024

Cyclosam is under clinical development by QSAM Therapeutics and currently in Phase I for Metastatic Prostate Cancer.

40

40

Pharmaceutical Technology

APRIL 6, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending AstraZeneca’s olaparib to treat early breast cancer and metastatic prostate cancer. It also updates NICE’s recommendation for olaparib for prostate cancer patients with BRCA1 or BRCA2 mutations.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

AUGUST 4, 2022

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy studies can be a hit-and-miss affair. Lenvima combination.

Chemotherapy 105

Chemotherapy Labelling FDA 105

Pharmaceutical Technology

DECEMBER 25, 2023

ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

European Pharmaceutical Review

DECEMBER 13, 2022

The European Commission (EC) has approved Pluvicto ® (lutetium (177Lu) vipivotide tetraxetan), the first targeted radioligand therapy commercially available for people with advanced prostate cancer. Clinical data that led to the European Commission’s approval. Additional regulatory approvals for Pluvicto ®.

Chemotherapy 59

Chemotherapy FDA 59

pharmaphorum

DECEMBER 5, 2022

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Chemotherapy 58

Chemotherapy Compounding Labelling FDA 58

Pharmaceutical Technology

DECEMBER 21, 2023

PF-07220060 is under clinical development by Pfizer and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

DECEMBER 5, 2023

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC).

40

40